China’s Manus raises over $500M in first funding round since split with Meta

Chinese AI lab Manus’ parent company, Butterfly Effect, said on Thursday in a WeChat post that it has raised more than $500 million, the company’s first funding round since Meta was forced to call off its $2 billion acquisition of the startup.

Boyu Capital and IDG Capital led the funding round, and existing shareholders Tencent, HSG (formerly known as Sequoia China), ZhenFund and others also participated. The AI company said it will continue hiring both at home and abroad.

Manus did not disclose its valuation, but it was last month said to be in talks with investors to raise $500 million at a $4 billion valuation.

Manus, which went viral following a demo of its AI agent last year, relocated its staff to Singapore in mid-2025 before announcing a $2 billion acquisition deal with Meta that December. The startup was said to be pulling in annual recurring revenue of over $100 million at the time.

In April, Chinese authorities ordered the AI startup to unwind the deal amid intensifying worries in China over losing AI talent and researchers to the West.

Manus in August resumed independent operations following the end of the Meta deal, and said it was required to delete some user data as part of the split. The company is also reported to be considering going public in Hong Kong, according to the report.

Manus did not respond to TechCrunch’s questions about its valuation.

Manus makes AI products and agents similar to what companies like Cursor, Lovable, and Replit offer. It offers a chatbot and vibe-coding tools to let users build apps and websites, create designs and presentations, generate video, and more.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

Kate Park is a reporter at TechCrunch, with a focus on technology, startups and venture capital in Asia. She previously was a financial journalist at Mergermarket covering M&A, private equity and venture capital.

View Bio